These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 38769817)

  • 41. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
    Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
    Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
    Wan G; Chen W; Khattab S; Roster K; Nguyen N; Yan B; Rajeh A; Seo J; Rashdan H; Zubiri L; Hadfield MJ; Demehri S; Yu KH; Lotter W; Gusev A; LeBoeuf NR; Reynolds KL; Kwatra SG; Semenov YR
    Lancet Oncol; 2024 Aug; 25(8):1053-1069. PubMed ID: 39025103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
    Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
    Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
    Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
    Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
    Mihic-Probst D; Reinehr M; Dettwiler S; Kolm I; Britschgi C; Kudura K; Maggio EM; Lenggenhager D; Rushing EJ
    Immunobiology; 2020 Sep; 225(5):152009. PubMed ID: 32962812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
    Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
    Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
    Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
    Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
    Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
    Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
    Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.